Intrommune Therapeutics Featured at Upcoming Investor Conferences
05 oct. 2020 14h55 HE
|
Intrommune Therapeutics
NEW YORK, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing patient-friendly food allergy therapies for peanut and other food allergies...
Media Alert: Interest in Peanut Allergy Market Heats up in the Wake of Aimmune/Nestlé Deal
01 sept. 2020 15h55 HE
|
Intrommune Therapeutics
NEW YORK, Sept. 01, 2020 (GLOBE NEWSWIRE) -- The recent $2.6 billion acquisition of Aimmune by Nestlé Health Science has helped shed light on the global peanut allergy problem. In January 2020,...
Asthma and Allergy Foundation of America (AAFA) Appoints Melanie Carver Chief Mission Officer
06 août 2020 08h53 HE
|
Asthma and Allergy Foundation of America
Washington, D.C., Aug. 06, 2020 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) is excited to announce Melanie Carver has been named Chief Mission Officer of the...
Survey Confirms Physician Interest in Peanut Allergy Immunotherapy
03 févr. 2020 09h04 HE
|
Intrommune Therapeutics
New York, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly immunotherapy platform for the treatment of peanut and other...
Intrommune Participates in 2019 Food Allergy Fund Summit
26 nov. 2019 15h41 HE
|
Intrommune Therapeutics
New York, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment for peanut and other food allergies delivered...
POISED Study Supports Risk of Cessation of Oral Immunotherapy for Peanut Allergy; PACE Study Indicates Safer Peanut Allergy Treatment Approaches are Needed
07 nov. 2019 10h00 HE
|
Intrommune Therapeutics
New York, Nov. 07, 2019 (GLOBE NEWSWIRE) -- A major study recently published in The Lancet, “Sustained outcomes in oral immunotherapy for peanut allergy (POISED study),” further validates the...
Intrommune Therapeutics Supports Outcome of FDA Allergenic Product Advisory Committee Vote
16 sept. 2019 14h25 HE
|
Intrommune Therapeutics
New York, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly immunotherapy platform for the treatment of peanut and...
Intrommune Therapeutics Receives Support from Allergy & Asthma Network
13 sept. 2019 09h05 HE
|
Intrommune Therapeutics
New York, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing the patient-friendly oral mucosal immunotherapy (OMIT) toothpaste platform for...
Newly Published Findings Validate Intrommune’s Approach to Treating Peanut and Other Food Allergies
05 sept. 2019 15h20 HE
|
Intrommune Therapeutics
New York, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly immunotherapy platform for the treatment of peanut and...
Intrommune Therapeutics Receives Formulation Patent Notice of Allowance
21 août 2019 14h41 HE
|
Intrommune Therapeutics
New York, Aug. 21, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, is...